About the webinar:
Watch this insightful webinar hosted by Taconic Biosciences, featuring Dr. Barry Bedell, MD, PhD, CEO and CSO of Biospective, as he explores the advanced characterization of mouse models engineered for preclinical testing of investigational treatments targeting neurodegenerative diseases such as Alzheimer’s disease, tauopathies, Parkinson’s disease, and Amyotrophic Lateral Sclerosis (ALS).
This session will highlight how developing animal models that closely reflect key aspects of human neuropathology, along with the discovery and validation of translational biomarkers, can significantly enhance the progression from early-stage research to clinical development. Biospective has taken a leading role in this area by creating and thoroughly characterizing models with pathology driven by misfolded proteins, including amyloid-beta, tau, alpha-synuclein, and TDP-43.
Dr. Bedell will share multi-modal data sets encompassing motor and behavioral assessments, in vivo imaging, and advanced immunohistochemistry and multiplex immunofluorescence analyses. The data will span across multiple model platforms, including those generated via adeno-associated virus (AAV) vectors, preformed fibrils (PFF), and traditional transgenic methods.
